This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Semaglutide significantly reduces weight and shows hepatoprotective and neuroprotective effects.
Why it matters
Understanding semaglutide's broader therapeutic potential could lead to new treatments for obesity and neurodegenerative diseases. Its approval for obesity management highlights its clinical relevance.
How the study worked
The study is a narrative review summarizing findings from various clinical and pre-clinical trials.
What this study cannot tell us
The review is based on existing studies and does not present new experimental data.
Read the original research
Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.
Pharmaceutical research, 39(6), 1233-1248
Citation
Mahapatra, Manoj K; Karuppasamy, Muthukumar; Sahoo, Biswa M. (2022). Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.. Pharmaceutical research, 39(6), 1233-1248. https://doi.org/10.1007/s11095-022-03302-1